

SenesTech Announces First Quarter Sales Progress

FLAGSTAFF, Ariz., May 2, 2017 /[PRNewswire](#)/ -- SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary technologies for managing animal pest populations through fertility control, today announced its progress towards commercialization during the first quarter, 2017.

"On January 23rd, with our technology and first product returned to our control we have moved swiftly to implement a commercialization plan," said Dr. Loretta P. Mayer, Chair, CEO and co-founder of SenesTech.



Progress and developments to date include:

- ContraPest is now approved in 48 states, with Florida and California in the final approval steps.
- An expanded manufacturing capacity will be online by the end of May.
- Product shipments have begun to customers, in our municipal, commercial and professional pest control operator (PCO) segments.
- Purchase proposals are out to additional customers in these segments, with expansion into animal health facilities (zoos and sanctuaries) and agriculture (protein production facilities).
- In Hawaii, a program is underway to assess the replacement of poison with ContraPest in sensitive island ecologies.
- Proposals for permission for conditional use (in advance of full registration) have been made in European and other overseas locales.

"We are actively responding to our increasing number of inquiries and refining our list of target segments based on these inquiries," continued Dr. Mayer. "With this information in hand, we intend to launch our first marketing campaign, which we call 'Project Arizona' to aim at highly poison-averse potential customers who we think are likely early adopters. Details on this exciting program will be released soon."

The Company expects to report first quarter financial results on or about May 11, 2017.

About SenesTech

SenesTech has developed an innovative technology for managing animal pest populations through fertility control as opposed to a lethal approach.

The Company's first fertility control product, ContraPest[®], is marketed for use initially in controlling rat infestations. ContraPest's novel technology and approach targets the reproductive capabilities of both sexes, inducing egg loss in female rodents and impairing sperm development in males. Using proprietary bait stations, ContraPest is dispensed in a highly palatable liquid formulation that promotes sustained consumption by rodent communities. ContraPest is designed, formulated and dispensed to be safe for handlers and non-target species such as wildlife, livestock and pets, in a biodegradable product. In contrast, the historical approach to managing rodent pest populations, rodenticides, carries a high risk of environmental contamination and the poisoning of non-target animals, pets and children.

We believe our non-lethal approach, targeting reproduction, is more humane, less harmful to the environment, and more effective in providing a sustainable solution to pest infestations than traditional lethal pest management methods. There is currently no other non-lethal fertility control product approved by the Food and Drug Administration (FDA), or the Environmental Protection Agency (EPA), for the management of rodent populations. We believe ContraPest[®] will establish a new paradigm in rodent control, resulting in improved

performance in rodent control over rodenticides, without the negative environmental effects of rodenticides. For more information visit the SenesTech website at www.senestech.com.

Safe Harbor Statement

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors and other risks identified in our filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACT:

Investor: Robert Blum, Joe Dorame, Joe Diaz, Lytham Partners, LLC, 602-889-9700,
senestech@lythampartners.com

Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc., 928-779-4143

SOURCE SenesTech, Inc.

<https://senestech.investorroom.com/2017-05-02-SenesTech-Announces-First-Quarter-Sales-Progress>